Skip to Content
Developmental Therapeutics Program (DTP)
Contact DTP
Show menu
Search this site
Last Updated: 05/10/22

Molecular Pharmacology Branch (MPB)

MPB’s mission is to improve the treatment of recalcitrant, rare and neglected cancers through the discovery of potential therapeutic targets, the screening of new agents, the identification of genomic vulnerabilities, and the identification of potential therapeutic combinations using state-of-the-art drug discovery, molecular characterization, and mechanism-of-action techniques and through interactions collaboration with the cancer research community and other NCI laboratories. To achieve these goals, the MPB operates five laboratories at the Frederick National Laboratories for Cancer Research: the NCI60 cell line screen, the Target Validation and Screening Laboratory which specializes in drug combination studies in patient-derived complex spheroids, the Organoids Laboratory, the Translational Support Laboratory and the Tubulin Biology Laboratory. MPB is currently focused on 3D patient-derived models with an emphasis on rare and recalcitrant cancers from the PDMR collection (

About the Branch Chief

Dr. Mary K. Wolpert, Ph.D. Dr. Beverly A. Teicher PhD is Chief of the Molecular Pharmaco-logy Branch at NCI, a position that she assumed in early 2011. One focus of the Molecular Pharmacology Branch is target and drug discovery for rare and recalcitrant cancers such as sarcoma and small cell lung cancer. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. More…